MeiraGTx (NASDAQ:MGTX) Issues Quarterly Earnings Results

MeiraGTx (NASDAQ:MGTX) announced its quarterly earnings data on Thursday. The company reported $0.19 EPS for the quarter, topping the consensus estimate of ($0.60) by $0.79, Zacks reports. MeiraGTx had a negative net margin of 615.27% and a negative return on equity of 1,065.47%. The business had revenue of $75.36 million for the quarter, compared to analyst estimates of $3.87 million.

MeiraGTx Stock Performance

MGTX stock traded down $0.02 during midday trading on Friday, reaching $7.52. 164,185 shares of the company’s stock traded hands, compared to its average volume of 402,552. The company has a 50-day moving average price of $7.57 and a two-hundred day moving average price of $7.94. The company has a debt-to-equity ratio of 26.29, a quick ratio of 0.22 and a current ratio of 0.22. MeiraGTx has a 52 week low of $4.55 and a 52 week high of $9.73. The firm has a market capitalization of $604.89 million, a PE ratio of -3.56 and a beta of 1.37.

Insider Activity at MeiraGTx

In other news, CEO Alexandria Forbes sold 62,000 shares of the firm’s stock in a transaction on Tuesday, March 24th. The stock was sold at an average price of $7.41, for a total value of $459,420.00. Following the completion of the transaction, the chief executive officer directly owned 1,449,695 shares of the company’s stock, valued at $10,742,239.95. This trade represents a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.50% of the stock is owned by insiders.

Institutional Investors Weigh In On MeiraGTx

Several large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its position in MeiraGTx by 43.8% during the second quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock worth $31,000 after buying an additional 1,466 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of MeiraGTx by 390.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock valued at $57,000 after acquiring an additional 7,005 shares in the last quarter. Abel Hall LLC purchased a new stake in shares of MeiraGTx in the 4th quarter valued at about $98,000. Hsbc Holdings PLC boosted its position in shares of MeiraGTx by 24.3% during the 4th quarter. Hsbc Holdings PLC now owns 23,792 shares of the company’s stock valued at $189,000 after acquiring an additional 4,649 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new position in shares of MeiraGTx during the fourth quarter worth about $213,000. Institutional investors own 67.48% of the company’s stock.

MeiraGTx News Summary

Here are the key news stories impacting MeiraGTx this week:

• Positive Sentiment: Q4 beat — MeiraGTx reported $0.19 EPS and $75.36M revenue, materially ahead of consensus (EPS vs. loss expectation and revenue well above estimates), supporting the view that recent program milestones are translating into revenue recognition and reducing short-term execution risk. View Press Release
• Positive Sentiment: FDA Breakthrough Therapy Designation — The FDA granted Breakthrough Therapy Designation to AAV2-hAQP1 for Grade 2/3 radiation‑induced xerostomia, accelerating regulatory pathway and raising the program’s commercial probability of success. Management also scheduled a program update with long-term data on April 16. Globe Newswire Release
• Positive Sentiment: Analyst upgrades / price-target increases — Bank of America raised its target to $16 and gave a Buy; Chardan reaffirmed a Buy and maintained a $35 target, signaling stronger sell‑side conviction and creating sizable upside vs. the current price. Benzinga
• Neutral Sentiment: Broader analyst coverage and institutional ownership — Market data shows mixed analyst ratings (Moderate Buy consensus) and ~67% institutional ownership, which can amplify moves but leaves room for divergent views. MarketBeat
• Negative Sentiment: Insider sale — CEO Alexandria Forbes sold 62,000 shares (~$459k), which may be perceived as profit-taking or reduce near‑term insider buying signal. InsiderTrades
• Negative Sentiment: Fundamentals remain challenged — Despite the beat, MeiraGTx still shows a negative net margin and ROE, low current/quick ratios and a high reported debt/equity metric, which keeps cash‑flow and funding risk top of mind for investors. MarketBeat fundamentals

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MeiraGTx in a report on Thursday, January 22nd. Bank of America increased their price objective on MeiraGTx from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday. Zacks Research raised MeiraGTx from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Finally, Chardan Capital restated a “buy” rating and issued a $35.00 target price on shares of MeiraGTx in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.33.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.